
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Direct-to-consumer (DTC) advertising is boosting prescription use, pharmaceutical companies are spending more on DTC ads, and FDA needs to act more quickly to remove false or misleading commercials from the air.
